February 27, 2026 — Chongqing Precision Biotech Co., Ltd. announced that results from a Phase 1 clinical study of its internally developed hypoxia-responsive CEA-targeted CAR-T cell therapy (PC13) have been published in Nature Cancer (impact factor: 28.5).The study, titled Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial (NCT05396300), reports the clinical evaluation of this investigational therapy.

The trial was conducted at the First Affiliated Hospital, Zhejiang University School of Medicine, and led by Prof. Fang Weijia and his team. PC13 is a hypoxia-responsive CAR-T product designed to target CEA-positive solid tumors. The study provides clinical evidence supporting the feasibility of tumor microenvironment-responsive CAR design and its potential therapeutic activity in solid tumors.